Dual-component CAR T cell therapy: targeting BCMA with convertible CAR and MicAbodies

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Abstract 3618: High-avidity BCMA CAR and high-affinity, non-cleavable CD16 Fc receptor incorporated in off-the-shelf CAR T cells promote multi-antigen targeting and durable anti-tumor cytotoxicity in the treatment of multiple myeloma2024 · 1 citations
2. 2Data from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
3. 3CAR-modified marrow infiltrating lymphocytes efficiently target malignant plasma cells with very low antigen density2026
4. 4Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma2024 · 4 citations
5. 5Engineering BCMA CAR T cells for myeloma-targeted cargo delivery2024 · 1 citations